Application for recombinant Insulin Human AF
- Application for recombinant Insulin Human AF
- Front Page
- Registrant group for Cetrimonium Bromide (CTAB)
- Registrant group for Reaction mass of C12 trimethylammonium bromide and C14 trimethylammonium bromide
- Registrant group for Tetradonium Bromide
- Applications for Quats
- Why us
- Download & Publications
- Contact us
Increase specific influenza production with recombinant insulin
Mammalian cells are considered an alternative to eggs for the production of influenza vaccines. HEK293SF-3F6 is a suspension GMP cell line that grows in serum-free media, and influenza production has been achieved in flasks and large bioreactors.
National Research Council Canada (NRC) in collaboration with Novo Nordisk Pharmatech (world’s largest supplier of recombinant insulin) has shown that addition of animal origin free insulin to commercial available media and in-house proprietary media in HEK 293SF-3F6 batch-mode culture, resulted in significant increases in cell growth, leading up to 4-fold increase compared to insulin free media formulations.
In addition to cell growth, the study aimed to address the effect of Insulin on HEK-based Influenza Production, since the effect on Influenza virus productivity was not known.
Insulin has been proved already to positively affect cell survival, by promoting anti-apoptotic and mitogenic pathways, to interact on cellular signalling pathways that are exploited by the influenza virus and it has the benefit of being already approved by regulatory agencies.
This study has shown that addition of animal origin free insulin to commercial available media and in-house proprietary media in HEK 293SF-3F6 micro-bioreactor culture, resulted in significant increase in H1N1 and H3N2 Influenza subtypes , leading to up to 1,9-fold increase compared to insulin free media formulations.